13012 Federal Register / Vol. 80, No. 48 / Thursday, March 12, 2015 / Notices 

OS specifically requests comments on 

(1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions, (2) the accuracy of the 

estimated burden, (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Terry S. Clark, 

Deputy Information Collection Clearance 

Officer. 

[FR Doc. 2015–05624 Filed 3–11–15; 8:45 am] 

BILLING CODE 4150–03–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; NCI 

Omnibus R03 & R21 SEP–12. 

Date: April 30, 2015. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Dona Love, Ph.D. 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, 9609 Medical 

Center Drive, Room 7W236, Bethesda, MD 

20850, 240–276–5264, donalove@

mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Omnibus 

SEP–10. 

Date: April 30, 2015. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W602, Rockville, MD 20850, (Telephone 

Conference Call). 

Contact Person: Delia Tang, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, 9609 

Medical Center Drive, Room 7W602, 

Bethesda, MD 20892, 240–276–6456, 

tangd@.mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http://

deainfo.nci.nih.gov/advisory/sep/sep.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: March 6, 2015. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–05568 Filed 3–11–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces a meeting for the initial 

review of applications in response to 

(FOA) DP15–005, Evaluation of a 

Stepped Care Approach for Perinatal 

Depression Treatment in Obstetrics and 

Gynecology Clinics. 

Time and Date: 10:00 a.m.–6:00 p.m., 

April 1, 2015 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to 

the public in accordance with 

provisions set forth in section 552b(c)(4) 

and (6), title 5 U.S. C., and the 

Determination of the Director, 

Management Analysis and Services 

Office, CDC, pursuant to Pub. L. 92–463. 

Matters for Discussion: The meeting 

will include the initial review, 

discussion, and evaluation of 

applications received in response to 

‘‘Evaluation of a Stepped Care Approach 

for Perinatal Depression Treatment in 

Obstetrics and Gynecology Clinics’’, 

DP15–005. 

Contact Person for More Information: 

M. Chris Langub, Ph.D., Scientific 

Review Officer, CDC, 4770 Buford 

Highway NE., Mailstop F–80, Atlanta, 

Georgia 30341, Telephone: (770) 488– 

3585, EEO6@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2015–05574 Filed 3–11–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces a meeting for the initial 

review of applications in response to 

(FOA) DP15–009, Improving 

Surveillance and Prevention of Epilepsy 

Burden in U.S. Communities. 

Time and Date: 10:00 a.m.—6:00 p.m., 

March 31, 2015 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters for Discussion: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Improving Surveillance and 

Prevention of Epilepsy Burden in US 

Communities’’, DP15–009. 

Contact Person for More Information: M. 

Chris Langub, Ph.D., Scientific Review 

Officer, CDC, 4770 Buford Highway, NE., 

Mailstop F–80, Atlanta, Georgia 30341, 

Telephone: (770) 488–3585, EEO6@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 


asabaliauskas on DSK5VPTVN1PROD with NOTICES